KCM
VRDN icon

Kennedy Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Kennedy Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,456
Closed -$959K – 744
2018
Q3 		$959K Sell
11,456
-123
-1% -$11.6K 0.02% 647
2018
Q2 		$1.11M Buy
+11,579
New +$1.22M 0.02% 662

Other funds holding VRDN

AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kennedy Capital Management's VRDN Position: Q4 2018 in Review

Kennedy Capital Management sold out of Viridian Therapeutics (VRDN) in Q4 2018, closing a stake of 11,456 shares — an estimated $959K sold.

Kennedy Capital Management first reported a position in VRDN in Q2 2018 and held it in 2 quarters. The position peaked at $1.11M in Q2 2018. 56 funds tracked by Wall St. Rank hold VRDN as of Q4 2018.

  • Kennedy Capital Management reported no remaining Viridian Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Kennedy Capital Management sold 11,456 Viridian Therapeutics shares in Q4 2018, an estimated $959K.
  • Kennedy Capital Management first reported a position in Viridian Therapeutics in Q2 2018 and held it in 2 quarters.
  • Kennedy Capital Management's Viridian Therapeutics position peaked at $1.11M in Q2 2018.
  • 56 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2018.

Based on Kennedy Capital Management's 13F filing for Q4 2018, filed 12 Feb 2019.